GenMark Diagnostics Guides to Q2 Revenues of $3.2M to $3.6M, Raises Full-year 2012 Revenue Guidance | GenomeWeb

NEW YORK (GenomeWeb News) – GenMark Diagnostics today provided second-quarter revenue guidance and raised its full-year 2012 revenue guidance.

For the quarter ending June 30, the Carlsbad, Calif.-based molecular testing firm said that revenues are anticipated to fall between $3.2 million and $3.6 million. Full-year 2012 revenues are now expected to top $15 million. GenMark said in its fourth-quarter and full-year 2011 earnings announcement that 2012 revenues would exceed $10 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.